We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Byotrol Plc | LSE:BYOT | London | Ordinary Share | GB00B0999995 | ORDS 0.25P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
0.35 | 0.45 | 0.40 | 0.40 | 0.40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 4.59M | -1.69M | -0.0037 | -1.08 | 1.82M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
11:45:12 | O | 56,272 | 0.35556 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
22/12/2023 | 11:44 | UKREG | Byotrol PLC Holding(s) in Company |
07/12/2023 | 11:49 | ALNC | Byotrol shares jump as optimistic despite half-year loss widening |
07/12/2023 | 07:00 | UKREG | Byotrol PLC Half-year Report |
14/11/2023 | 14:21 | ALNC | TRADING UPDATES: Byotrol interim sales flat; Argo loss narrows |
14/11/2023 | 07:00 | UKREG | Byotrol PLC Trading Update |
14/11/2023 | 07:00 | RNSNON | Byotrol PLC Launch of PROCESSUS(R) Instrument Decontamination |
09/11/2023 | 15:43 | UKREG | Byotrol PLC Holding(s) in Company |
27/9/2023 | 12:20 | ALNC | Byotrol CEO Pinto steps down; ex-CEO appointed as interim |
27/9/2023 | 06:00 | UKREG | Byotrol PLC Board Changes |
13/9/2023 | 14:33 | UKREG | Byotrol PLC Result of AGM |
Byotrol (BYOT) Share Charts1 Year Byotrol Chart |
|
1 Month Byotrol Chart |
Intraday Byotrol Chart |
Date | Time | Title | Posts |
---|---|---|---|
18/3/2024 | 19:29 | BYOTROL-CAN DELIVER AMAZING RESULTS | 12,555 |
09/8/2022 | 07:34 | TRADING4GOOD FROM LSE | 2 |
24/6/2022 | 07:31 | Byot | - |
13/4/2020 | 20:14 | Byotrol (BYOT) One to Watch on Wednesday | 2 |
27/2/2016 | 19:04 | Byotrol:::::::::Cleaning Up | 45 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
11:45:14 | 0.36 | 56,272 | 200.08 | O |
08:31:08 | 0.41 | 100,000 | 412.50 | O |
08:31:08 | 0.41 | 125,000 | 515.63 | O |
2024-03-18 15:49:47 | 0.41 | 125,000 | 515.63 | O |
2024-03-18 14:40:44 | 0.35 | 282,986 | 998.94 | O |
Top Posts |
---|
Posted at 19/3/2024 08:20 by Byotrol Daily Update Byotrol Plc is listed in the Chemicals & Chem Preps, Nec sector of the London Stock Exchange with ticker BYOT. The last closing price for Byotrol was 0.40p.Byotrol currently has 453,890,405 shares in issue. The market capitalisation of Byotrol is £1,815,562. Byotrol has a price to earnings ratio (PE ratio) of -1.08. This morning BYOT shares opened at 0.40p |
Posted at 16/3/2024 13:46 by maxk Well, it cant be a share price crash ... that's bin done and dusted. |
Posted at 11/3/2024 07:28 by best1467 Weak Negotiations on licensing deals is the problem Look at the legacy Tristel deal achieved nothing now they introduce Cache and Byotrol receiving Zero.Shafted again I suggest that original deal was a stalling tactic while the cache range got developed.I will tell you all now Cache sales will be growing at double digits throughout Europe from 2024 and worldwide to follow. That’s the reason they have a turbo charged rating not to mention the extremely aggressive dividend policy interm doulded this Year payed later this month 10 x the current share price here |
Posted at 28/2/2024 15:46 by football Byotrol plcByotrol plc🎉 We're thrilled to share some exciting news! As part of our commitment to championing positive change and inclusivity, Byotrol is proud to sponsor an inspiring initiative for International Women's Day. something for the trolls to get excited about |
Posted at 28/2/2024 11:09 by bomber13 We are now back to share price levels that preceded the interims on 7th December .The current market cap is now barely more than Byotrol's interim turnover of just over £2m , and well below the £4.7m pencilled in by Cavendish for their full year to March 2024 . The EV/sales is just 0.6X . Even by AIM standards this valuation is strikingly poor . If we are to believe the Chairman's narrative , all KPI's are improving , rebranding has gone well , margins are on the up , and we are promised a material uplift in super high margin licencing revenues in full year 2025 . What better time for a new CEO to join the company ? And if all else fails , here is what he added to his interim statement - " The Board regularly reviews whether we can achieve our targets as an independent, listed company and has concluded for the time being that we can. We are now keeping this conclusion under frequent review and will not hesitate to take a different route if it will lead to better returns for shareholders." |
Posted at 07/12/2023 11:15 by mudbath Byotrol's decimated share price reflects the significant possibility that a delisting lies ahead.When/if announced the share price could well implode even further. Therein would lie the main opportunity. |
Posted at 30/11/2023 13:16 by sikhthetech 1gw#12222 "They have called out disappointing sales in Human Healthcare in H1" I warned about low consumer sales over 3 years ago, when you were misleading readers about sales, Finncap being conservative etc I take it you're not looking for an excuse to sell. That'll be disgraceful behaviour wouldn't it? Try and be honest for once. I see you/your mates are ramping HVO, Polb, SLN, TRMR. Given you portray yourself as a well researched poster, why do the vast majority of your shares crash after you have ramped them? You make a dodgy 2nd hand car salesman sound honest. How many multiple ids do you have and why? sikhthetech - 04 Dec 2022 - 20:27:36 - 10513 of 12322 BYOTROL-CAN DELIVER AMAZING RESULTS - BYOT 1gw, "I think Amazon is a relatively new endeavour for byotrol." It's jam tomorrow. As you very well know during the biggest pandemic to hit the world in 100yrs, Byot had a £590k (yes k) increase in GLOBAL consumer sales. And that was because there was a world wide shortage so people had no alternative. As I said at the time, the pandemic was the golden opportunity presented on a plate but they missed it. Consumer sales a virtually non-existent and therefore jam tomorrow. Your jam tomorrow is endless and repeated every few months for years but never materialised. Btw how did Hycolin do on Amazon despite being originally listed last year??? You're very selective in your comments and have a selective memory depending on your agenda, which currently is ramping. H1 results possibly due this week. Best see what they say rather than baseless jam tomorrow fro (if going by last year) sikhthetech - 07 Jan 2021 - 14:57:21 - 7339 of 8923 1gw, Facts from their H1-2021 accounts published last month. Rest is jam tomorrow. £590k (yes k) increase in global consumer sales when there's the biggest pandemic to hit the globe is not impressive. So with the biggest pandemic to strike in a century they managed £997k (ex-royalty & licensing) of consumer sales! That includes Boots, Homeandcleaning, direct website sales, global sales. Consumer: "H1 revenues more than doubled to £1.01m from £0.41m, including a small amount of IP-based income, versus nil IP income in the comparable period. Gross profit (on products) increased to £0.43m from £0.17m. " "Elsewhere, sales across existing customers all increased in this segment, especially into Japan via our longstanding agents in pet and healthcare." 1gw - 16 Nov 2023 - 12:28:44 - 12222 of 12322 BYOTROL-CAN DELIVER AMAZING RESULTS They have called out disappointing sales in Human Healthcare in H1 |
Posted at 26/10/2023 12:34 by loafofbread 2 weeks before he left he was still buying shares and owns 1.5% so alongside the rest of the BOD plenty to lose unless they sort this out.My take is someone is booking the loss for 28% CGT offset. Byotrol PLC 08 September 2023 Byotrol Plc ("Byotrol" or the "Company") Director Dealing Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, announces that on the 8(th) of September 2023, the wife of Vivan Pinto, CEO of the Company, purchased a total of 400,000 ordinary shares of 0.25p each ("Ordinary Shares") at an average price of 1.65p per Ordinary Share (the "Purchase"). Following the Purchase, Vivan Pinto's beneficial holding (including those held by his wife) is 2,900,000 Ordinary Shares, representing 0.64% of the total voting rights of the Company. As announced on 28 July 2022, Vivan Pinto subscribed for convertible loan notes in the Company, which if converted would represent an additional 0.7% of the total voting rights of the Company. |
Posted at 08/9/2023 11:56 by loafofbread At least we know where our supply of Brown seaweed will be coming from and our first partnership/developm06 July 2023 Byotrol Plc ("Byotrol" or the "Company") Patent Granted for Novel Anti-viral Seaweed Extract Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, is pleased to report the approval today of a UK patent following its discovery of unique anti-viral properties of certain enhanced extracts of commonly available brown seaweed. The award is a result of many years of research by Byotrol's technical team at its laboratories at Thornton Science Park, a University of Chester campus, and has been supported by the research scientists at the University of Liverpool led by Professor James Stewart, and by funding received from the Biotechnology and Biological Sciences Research Council (BBSRC) and Innovate UK. The grant of the patent application gives Byotrol validated, valuable and protected intellectual property, to support the development of commercial relationships. In the UK and Europe, seaweed extracts are not as yet approved as active materials for biocidal products, Byotrol's established area of expertise. So, we are now actively exploring alternative applications in very sizeable markets such as over-the-counter (OTC) products for the prophylactic treatment of viral conditions including colds, flu, coronaviruses and cold sores. Byotrol Plc's Chairman, Dr Trevor Francis, comments: "We are delighted to have secured the first patent for our seaweed-based anti-viral technologies. It is another good indication of the quality of our technical capability, and it will most certainly help us as we intensify the search for commercial partners. It also adds to our already significant level of intellectual property in antimicrobials. "This patent further confirms Byotrol's commitment to developing and commercializing natural and sustainable antimicrobial actives." |
Posted at 23/8/2023 06:03 by football Todays RNs WednesdayByotrol PLC Investor Presentation via Investor Meet Company 23/08/2023 7:00am RNS Non-Regulatory TIDMBYOT Byotrol PLC 23 August 2023 RNS Reach Byotrol plc ("Byotrol" or the "Company") Investor Presentation via Investor Meet Company Byotrol plc (AIM: BYOT), the specialist infection prevention and control company is pleased to announce that Vivan Pinto, CEO, David Traynor, Executive Director, and Chris Sedwell, CFO, will provide a live presentation relating to the Full Year Results via Investor Meet Company on 8th Sep 2023 at 11:00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet BYOTROL PLC via: Investors who already follow BYOTROL PLC on the Investor Meet Company platform will automatically be invited. For further information, visit www.byotrolplc.com , follow on twitter @byotrol, or contact |
Posted at 27/6/2023 07:04 by 1gw best - I think this is just the nature of the game in FMCG. Product claims are vital to marketing and product ingredients may be regarded as trade secrets, except to the extent that they have to be disclosed for regulatory reasons (e.g. "active" ingredients).If byotrol knows that Dettol 24 is an Actizone product because Solvay has told it so under the terms of a non-disclosure agreement then byotrol can't share that with shareholders (without Solvay's agreement). If byotrol doesn't know that Dettol 24 is an Actizone product then byotrol is presumably free to share its informed opinion that it looks like an Actizone product. So do shareholders actually want byotrol to ask Solvay (and then be bound by the NDA) given the weight of evidence that Dettol 24 is an Actizone product? What byotrol should be doing is trying to track penetration of Dettol 24 and estimate sales so that it can sense-check statements of sales issued by Solvay to byotrol under the commission agreement. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |